[1] Iftikhar M, Frey J, Shohan MJ, Malek S, Mousa SA (2021) Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy. Pharmacol Ther 220:107719. https://doi.org/10.1016/j.pharmthera.2020.107719
[2] MacKintosh EW, Chen ML, Benditt JO (2020) Lifetime Care of Duchenne Muscular Dystrophy. Sleep Med Clin 15:485–95. https://doi.org/10.1016/j.jsmc.2020.08.011
[3] Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17:251–67. https://doi.org/10.1016/S1474-4422(18)30024-3
[4] Suthar R, Reddy B, Malviya M, Sirari T, Attri S, Patial A, Tageja M, Didwal G, Khandelwal N, Saini A, Saini L, Sahu J, Dayal D, Sankhyan N (2021) Bone density and bone health alteration in boys with duchenne muscular dystrophy: A prospective observational study. J Pediatr Endocrinol Metab 34:573–81. https://doi.org/10.1515/jpem-2020-0680
[5] Ronsley R, Islam N, Kang M, Nadel H, Reilly C, Metzger D, Selby K, Panagiotopoulos C (2020) Effects of Bisphosphonate Therapy on Bone Mineral Density in Boys with Duchenne Muscular Dystrophy. Clin Med Insights Endocrinol Diabetes 13. https://doi.org/10.1177/1179551420972400
[6] Zacharin M, Lim A, Gryllakis J, Siafarikas A, Jefferies C, Briody J, Heather N, Pitkin J, Emmanuel J, Lee KJ, Wang X, Simm PJ, Munns CF (2021) Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy. J Clin Endocrinol Metab 106:2328–42. https://doi.org/10.1210/clinem/dgab302
[7] King WM, Kissel JT, Visy D, Goel PK, Matkovic V. Skeletal health in Duchenne dystrophy: Bone-size and subcranial dual-energy X-ray absorptiometry analyses. Muscle Nerve 2014;49:512–9. https://doi.org/10.1002/mus.23963
[8] Barzegar M, Elnaz N, Perinaz H, Shadi S, Sanaz T (2018) Bone mineral density and bone metabolism in patients with Duchenne muscular dystrophy. Iran J Child Neurol 12:77–83
[9] Crabtree NJ, Roper H, McMurchie H, Shaw NJ (2010) Regional Changes in Bone Area and Bone Mineral Content in Boys with Duchenne Muscular Dystrophy Receiving Corticosteroid Therapy. J Pediatr 156:450-455.e1. https://doi.org/10.1016/j.jpeds.2009.09.010
[10] Mayo AL, Craven BC, McAdam LC, Biggar WD (2012) Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy. Neuromuscul Disord 22:1040–5. https://doi.org/10.1016/j.nmd.2012.06.354
[11] Cruz-Guzmán OR, Rodríguez-Cruz M, Almeida-Becerril T, Maldonado-Hernández J, Baeza CW (2019) Muscle function and age are associated with loss of bone mineral density in Duchenne muscular dystrophy. Muscle Nerve 59:417–21. https://doi.org/10.1002/mus.26416
[12] Cirillo D, Hart S, Reich R, Mason T (2018) Height Measures: Evaluating Alternatives to Standing Height in the Ambulatory Setting. Clin J Oncol Nurs 22:529–33. https://doi.org/10.1188/18.CJON.529-533
[13] Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J (2007) Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 85:660–7. https://doi.org/10.2471/BLT
[14] Growth reference data for 5-19 years (2007) World Health Organization. http://www.who.int/growthref/en/
[15] WHO Expert Committee on Physical Status: the Use and Interpretation of Anthropometry (1995) Physical status : the use of and interpretation of anthropometry , report of a WHO expert committee. World Health Organization. https://apps.who.int/iris/handle/10665/37003
[16] Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Básica (2011) Orientações para a coleta e análise de dados antropométricos em serviços de saúde : Norma Técnica do Sistema de Vigilância Alimentar e Nutricional - SISVAN / Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Atenção Básica. – Brasília: Ministério da Saúde. 76 p https://bvsms.saude.gov.br/bvs/publicacoes/orientacoes_coleta_analise_dados_antropometricos.pdf
[17] ISCD (2019) Skeletal Health Assessment In Children from Infancy to Adolescence. Official Positions Pediatric. The International Society for Clinical Densitometry. https://iscd.org/learn/official-positions/pediatric-positions/
[18] Salera S, Menni F, Moggio M, Guez S, Sciacco M, Esposito S (2017) Nutritional challenges in duchenne muscular dystrophy. Nutrients 9:1–10. https://doi.org/10.3390/nu9060594
[19] Larson CM, Henderson RC (2000) Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 20:71–4. https://doi.org/10.1097/01241398-200001000-00016
[20] Bierhals IO, dos Santos Vaz J, Bielemann RM, de Mola CL, Barros FC, Gonçalves H, Wehrmeister FC, Assunção MCF (2019) Associations between body mass index, body composition and bone density in young adults: findings from a southern Brazilian cohort. BMC Musculoskelet Disord 20:322. https://doi.org/10.1186/s12891-019-2656-3
[21] Davis J, Samuels E, Mullins L. Nutrition Considerations in Duchenne Muscular Dystrophy 2015. https://doi.org/10.1177/0884533615586202
[22] Tung JY, Lam T, Chan, SH (2021) Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment. J Bone Miner Metab 39: 606–611. https://doi.org/10.1007/s00774-020-01196-w
[23] Weber DR, Hadjiyannakis S, McMillan HJ, Noritz G, Ward LM (2018) Obesity and endocrine management of the patient with Duchenne muscular dystrophy. Physiol Behav 142:43–52. https://doi.org/10.1542/peds.2018-0333F
[24] Klein GL (2015) The effect of glucocorticoids on bone and muscle. Osteoporos Sarcopenia 1:39–45. https://doi.org/10.1016/j.afos.2015.07.008
[25] Singh A, Schaeffer EK, Reilly CW (2018) Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort. J Pediatr Orthop 38:320–4. https://doi.org/10.1097/BPO.0000000000000817
[26] Perera N, Farrar F (2015) Bone Health in Children with Duchenne Muscular Dystrophy: A Review. Pediatr Ther 5:3. https://doi.org/10.4172/2161-0665.1000252
[27] Lee SLK, Lim A, Munns C, Simm PJ, Zacharin M (2020) Effect of Testosterone Treatment for Delayed Puberty in Duchenne Muscular Dystrophy. Horm Res Paediatr 93:108–18. https://doi.org/10.1159/000508290
[28] Longui CA (2007) Glucocorticoid therapy: minimizing side effects. J Pediatr (Rio J) 83:163–71. https://doi.org/10.2223/jped.1713
[29] Wood CL, Cheetham TD, Hollingsworth KG, Guglieri M, Ailins-Sahun Y, Punniyakodi S, Mayhew A, Straub V (2019) Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne muscular dystrophy. BMC Pediatr 19:1–12. https://doi.org/10.1186/s12887-019-1503-x
[30] Gilsanz V, Chalfant J, Kalkwarf H, Zemel B, Lappe J, Oberfield S, Shepherd J, Wren T, Winer K (2016) Age at Onset of Puberty Predicts Bone Mass in Young Adulthood. J Pediatr 158:100–5. https://doi.org/10.1016/j.jpeds.2010.06.054
[31] Vaitkeviciute D, Lätt E, Mäestu J, Jürimäe T, Saar M, Purge P, Maasalu K, Jürimäe J (2016) Longitudinal associations between bone and adipose tissue biochemical markers with bone mineralization in boys during puberty. BMC Pediatr 16:102. https://doi.org/10.1186/s12887-016-0647-1
[32] Takaso M, Nakazawa T, Imura T, Ueno M, Saito W, Shintani R, Takahashi K, Yamazaki M, Ohtori S, Okamoto M, Masaki T, Okamoto H, Okutomi T, Ishii K, Ueda Y (2010) Can the caudal extent of fusion in the surgical treatment of scoliosis in Duchenne muscular dystrophy be stopped at lumbar 5? Eur Spine J 19:787–96. https://doi.org/10.1007/s00586-010-1347-4
[33] Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, DesClouds P, Cram D, Page M, Konji VN, Lentle B, Ward LM (2017) The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int 28:597–608. https://doi.org/10.1007/s00198-016-3774-5
[34] Ward LM, Hadjiyannakis S, McMillan HJ, Noritz G, Weber DR (2018) Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics 142:S34–42. https://doi.org/10.1542/peds.2018-0333E
[35] Novotny SA, Warren GL, Lin AS, Guldberg RE, Baltgalvis KA, Lowe DA (2012) Prednisolone treatment and restricted physical activity further compromise bone of MDX mice. J Musculoskelet Neuronal Interact 12:16–23
[36] Crabtree NJ, Roper H, Shaw NJ (2022) Cessation of ambulation results in a dramatic loss of trabecular bone density in boys with Duchenne muscular dystrophy (DMD). Bone 154. https://doi.org/10.1016/j.bone.2021.116248 .